Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on central nervous system disorders, with three FDA‑approved U.S. products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness in obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine.
Total revenues from these three products reached $638.5 million in 2025, a 66% increase over 2024, reflecting rapid commercial ramp. The company is advancing a broad late‑stage pipeline, including AXS‑05 for Alzheimer’s disease agitation under FDA Priority Review with a PDUFA target date of April 30, 2026, multiple Phase 3 programs for solriamfetol in ADHD, depression with daytime sleepiness, binge eating disorder, and shift work disorder, and AXS‑12 for narcolepsy supported by positive Phase 2 and 3 data and Orphan Drug status.
Axsome is also developing AXS‑14 for fibromyalgia following an earlier Refusal to File, and AXS‑17 for epilepsy acquired via the Baergic Bio transaction. As of February 16, 2026, the company had 51,153,289 common shares outstanding and reported extensive global patent coverage and settled generic challenges that generally protect key franchises into the late 2030s and early 2040s.
Axsome Therapeutics reported strong growth for the fourth quarter and full year 2025, with total net product revenue of $196.0 million in Q4 and $638.5 million for the year, up 65% and 66% from 2024. Growth was led by AUVELITY with 2025 sales of $507.1 million and SUNOSI with $124.8 million, plus initial SYMBRAVO contributions of $6.6 million.
The company’s net loss narrowed to $183.2 million in 2025 from $287.2 million in 2024, despite higher SG&A spending of $570.6 million to support commercialization. Cash and cash equivalents were $322.9 million as of December 31, 2025.
Axsome highlighted a rich CNS pipeline, including Priority Review for its sNDA for AXS-05 in Alzheimer’s disease agitation with a PDUFA target date of April 30, 2026, an NDA submission for AXS-12 in narcolepsy planned this quarter, multiple Phase 3 solriamfetol trials, and the newly acquired epilepsy candidate AXS-17.
Axsome Therapeutics has entered into a settlement agreement with Alkem Laboratories resolving U.S. patent litigation over Axsome’s wake‑promoting drug SUNOSI (solriamfetol). The case arose after Alkem filed an Abbreviated New Drug Application seeking approval to market a generic SUNOSI in the United States.
Under the settlement, Axsome will grant Alkem a license to sell its generic SUNOSI beginning on or after September 1, 2040 if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040 if no pediatric exclusivity is granted, in each case subject to FDA approval and customary conditions. The settlement will be submitted to the FTC and DoJ for review, and Axsome notes that similar patent litigation against another party regarding SUNOSI remains pending in the same court.
Axsome Therapeutics director Mark Coleman reported an option exercise and related share holdings. On February 10, 2026, he exercised 5,193 stock options at an exercise price of $8.02 per share and held the underlying common stock rather than selling it. Following this transaction, he directly owned 53,405 shares of common stock. In addition, 403,856 shares of common stock are held indirectly through an entity over which he has voting and dispositive power, so he is deemed the indirect beneficial owner of those shares.
Axsome Therapeutics CEO Herriot Tabuteau reported an option exercise and share sale. On 02/02/2026, he exercised 32,410 stock options at $8.02 per share and acquired the same number of common shares. That same day, he sold 32,410 common shares at a weighted average price of $185.60 under a pre-approved Rule 10b5-1 plan that has now been completed.
After these transactions, Tabuteau directly holds 7,229 shares of Axsome common stock and is also deemed the indirect beneficial owner of 7,344,500 additional shares held by an entity over which he has voting and dispositive power.
Axsome Therapeutics insider plans to sell common stock. A Form 144 notice reports a proposed sale of 32,410 shares of Axsome Therapeutics common stock through Goldman Sachs & Co. LLC, with an aggregate market value of
The shares were acquired on
Axsome Therapeutics Chief Financial Officer Nick Pizzie reported an option exercise and related share sale. On January 22, 2026, he exercised stock options for 12,000 shares of common stock at an exercise price of
The same day, he sold 12,000 shares of Axsome common stock in open-market transactions at a weighted average sale price of
Axsome Therapeutics Chief Commercial Officer Ari Maizel reports an option exercise and share sale. On January 21, 2026, he exercised a stock option for 7,500 shares of common stock at an exercise price of $70.73 per share. The same day, he sold 7,500 shares of common stock in open-market transactions at a weighted average price of $184.44 per share, fully disposing of the acquired shares.
The filing notes that these transactions were made under a pre-approved Rule 10b5-1 trading plan, which is designed to allow preset trading of shares. Following the option transaction, Maizel beneficially owns 31,210 stock options directly, with no common shares reported as directly owned after the sale.
Axsome Therapeutics, Inc. filed a notice of proposed insider sale of 12,000 common shares under Rule 144. The shares are to be sold through Charles Schwab & Co., Inc. on NASDAQ, with an aggregate market value of
The 12,000 shares were acquired on
Axsome Therapeutics, Inc. has a planned sale of 7,500 shares of common stock, according to a Form 144 notice. The shares are to be sold through Charles Schwab & Co., Inc. on the NASDAQ, with an aggregate market value of $1,383,327.00. The filing lists total common shares outstanding as 50,412,640.
The 7,500 shares were acquired on 01/21/2026 via an employee stock option exercise from Axsome Therapeutics, Inc., using a broker payment for a cashless exercise on the same date. The Form 144 also includes a representation that the seller does not know of any undisclosed material adverse information about the issuer.